VNRX - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited's Fourth Quarter and Full Year 2020 Earnings Conference Call.

During today's presentation, all parties will be in a listen-only mode.

Following the presentation, the conference call will be opened for questions. [Operator Instructions]. recorded XX, being is conference today, XXXX. March This the over to now like call turn to I'd Mr. conference Powell. Scott Please go ahead, Scott.

Scott Powell

cover operating Thank upcoming you, and discussion VolitionRx will of for earnings full conference financial and welcome along activities everyone Limited. to year of our This with fourth recent for milestones. the results today's XXXX, call Volition's quarter and a call key and

Cameron we a call Chief remarks, Jake prepared our will President Mr. question-and-answer today Officer. Scientific Also our conference Hughes, to our open Micallef, Executive Following call Financial Chief our session. on are Terig Dr. Officer; Reynolds, and the Chief Officer; Mr. and appointed recently

to future actual us. involve be assumptions. may of the current that and Before of views events risks, or XXXX. future These significantly uncertainties these expressed the covered based Litigation forward-looking these beliefs, we upon information Actual our that of statements everyone on the Reform future available as factors events, like implied the materially achievements concerning by Act based may are on a different or statements vary used cause will some based as remind number we Safe Harbor performance include well Private statements information assumptions under begin, Securities provisions of to this our on I'd from to results, results statements results discussed Because reflect or conference currently these call have statements.

Reynolds. call Exchange filings made turn with update report course We XX-Q, to other the I'd on Form this to Securities reports Mr. our Chief in President obligation and XX-K, Form any and the have operations our our now Cameron of Officer, during most identified Executive like undertake forward-looking Cameron? various call. on Commission. recent any annual statements to factors over risk with do associated and We not the quarterly

Cameron Reynolds

lab our earnings difficult call disruptive that we appreciate that significant times. I and the in progress and I the work start all to have the few we season. the the middle for main our efforts. opened by reliable, a prouder yet over of wide busy XXXX Silver keep of given conference think Despite new throughout production I'd operational recognizing year, areas XXXX,now the of many in a have lockdown, ways such call into past One hard again it, to and everyone, the done teams business influential the technology of Volition's platform can joining into have reproducible and could of and facility be their today. made quarter be by range areas. will first like you, we managed especially of stable, worldwide Thank commitment not during highly such amazing and indeed these

who the have XXXX product we all this over the will year. cover our annual our and and being of on discussing the will start passing then launches, last the I in by Before briefly financials, moving today reminder made progress Terig, to a highlights our call,

especially our strongly, exciting of achieved of January in by Optima the then and our first milestones by year traded We between. Decemberand lots launching Cancer closing Vet this have in Test Nu.Q acquisition Screening product in

leader truly study And of use the April in helped results, proof-of-concept acquisition these is know tests,the last Society we Nu.Q secure the components was portfolio, of year on of Nu.Q This NETosis, nucleosomes, published the transfer of submitted, a how product we the wide Throughout our and opinion our effort now year, the in and large continued we, range most the hold a including other A&M. by COVID-XX a only flexibility of and patent This October As house. recombinant the Nu.Q complete, roundtable and for have now a and team diseases. capability our with Tests application we to patents and of flexibility Veterinary reminder, strategic in amazing Nu.Q Optima end, during year. further fantastic pending. always, additional we as of XX by patents patents manufacture key yet as near-term our of XXXX, relation of year with to with of launch Vet conference a key XXXX opportunities reflect new key technology Cancer strengthen in the refocusing aspect now event pandemic team. data intellectual of test. platform granted all It we components being is the the truly is all to pivotal And Screening one XX worldwide, show a property that use key to calibrants.The remarkable of in hosted the reported supply is a which Texas Cancer success.

abstracts our of various with Nu.Q performance on studies in as conferences, cancer at be conducted Nu.Q notably to as lung number lung blood with a U.S. Capture. to at ASCO data both presented and/or our published most cancer, performance October Virtual to we cancer also featuring respect Day well two announced Markets At technology for and data We our in commitments the XXXX,

the or expected year. which from first study of NHL first the NHL now the cancer a Non-Hodgkin’s up are into types second of studies response studies study X,XXX The Both results treatment most the this regulatory scale subjects treatment next out the yearand aggressive of study is XXX(k) the to study a And the large likely five underway, response Lymphoma. the half these is later monitoring within proof-of-concept most the in for for DLBCL. first read common from regulatory of

that had a Officer So, lot our XXXX. go new have allow we on financing significantly of Chief over please action our you results to to Terig, to recent me XXXX XXXX have take before for details, Hughes, cash will key an Financial strengthened on you. and transactions who from have start the update more Board, an you into packed the position. provide review have the Terig I through But introduce financial and great

Terig Hughes

earnings joining today. I forward you financial now the thank our of Thanks key meeting everyone, results. very will possible. look much, summary of call Cameron. when provide many in-person a And for I you, to

and in and out at were For as year net $XX research COVID-XX million million reported development quarter in with spending our driven cash aftermarket common non-dilutive Invest. loss and the the our program. to XXXX, Optima NETosis. act underwritten cash distribution the of the we closed a our award predominantly employee have an year by at December which in equivalents Region, approximately as XXXX and period of compared of a by to-date, key million the first of of in increased over $X the loss $XX.X adding made strengthened the we cash million the as spending, to million this as year. January, February, through approximately prior $XX.X well directed investments level $XX.X ended in Despite higher the prior an research of million XXXX. Furthermore, the to to equity through as expanding result million and spending, securing public to And Namur XX, this, funding $XX.X aggregate XXXXreflecting $XX.X and of from well was with net announce Walloon delighted by XXXX, supply we components of $X.X manufacture of higher stock balance compared our through offering in higher sheet end approximately million, during significantly we of in team we acquisition, This

Walloon Volition We Walloon $XX from long like for well publicly to have approximately funding, Walloon Namur as Nicolas as and Willy Renaud have support. a history financial including and million the Economy, to-date support thank non-dilutive Invest in the their Government, Vice Delahaye of from recent this Borsus, We President Hattiez the most for awarded continued Minister agencies assistance of of the award. Region, who the would

to recap.Before which the totalled we in approximately cash and million, Company's carefully. into just our the have our manage have cash far the history. cash ever XXXX, thus continue $XX by So position we account is in equivalents had incurred expenditures far Nevertheless, expenses we taking to strongest

burn it In our of with Cameron will we earning achieve pass million month. was additional calls. product flexibility updates launches weather Our as both on make us strong product to we quarter our final we're per an many average milestones, provide updates. in to And I through I expect summary, pandemic. financial the providing our back future our continuing slightly operational Overall, XXXX platform. And expansion and increase position, rate of towards that, the great and further for would runway periodic a to to investments approximately $X.X and a will

Cameron Reynolds

have you Board. delighted balance absolutely I'm sheet ever strongest we've hadand to have Terig, Thanks the great and to on

Forterre, Chief In to welcome well team to newly for Mark Gaetan to founding the also promotion our Commercial Officer. Chief role new as fact, his as one for advisors Dr. our Michel Technology to Officer, Chief Eccleston, team, his like and I'd the Gael of promotion talking while publicly executive Officer congratulate of Operating members, our management Ms. created of

As hub for research All team appointments key strengthen company,we the their and team. to roles experience are focus production these these to lab to development our aim now announce with this a strong we leadership we're proud absolutely a for that and key to and are four our Also, management year. provide to point-of-view, strong to are appointments. we transitioning Belgium. bring product from components very expansion several a respective company achieve One, expertise certification global commercial and to today the products very a our Silver and full of our in components later have an plan ISO from I'm close happy to thrilled opened producing

fit Region, As low. previous of relatively grants the our purchase helping and costs the estate the burn supported again and vast loans majority rates non-dilutive from with Namur through transactions, were real to our keep out

in process at manufacture nucleosomes, diagnostic act materials We are our calibrantin addition such as our key elements raw full of our we’ll products. kits the into are which assays, large antibodies And recombinant well to indeed, as Nu.Q that scale, finalized. branded to once producing

for commercial elements that products opening and processing Vet on cost could expect new to and manufacture be sale installing We're great Nu.Q Plus, for road Silver lab. for We on could service sale current components One happier I diverse sample our Europe, to a revenue in also Europe situated including this stream. suitable in-house, parties new for find not our One facility all sample purposes, in external it's offer processingfor closely undertake that CE-Marked we will brings forward so a Silver beyond. the and thereby key another trial supply facility, the The our clinical of and site exciting lab in both future which step it but time a reduce of steplater. of the really definitely of our also any of chain, and reduce should production an assay of is securing elements should turn, in cost It development. for these more

be first was from will addition experience proven excellent in And Speaking Emmanuel revenue which update been our recently, and having we so of our team, field delighted you appointed research results our of I forward road. to and and to at in Kelly, quarterly in Vela. Officer of of has Emmanuel worked work Many on been brings expansion, the help Silver fourth generating winding Demillecamps, California discovery with drive Volition we help May. Volition his led initial in This Chief of an of Emmanuel have December. to most the has he innovation earnings Europe. Europe, State edge laboratory a on and long us San our we revenue. hard focuses leap has Roche, projects opened lab facility. regards in product a excellent from us in revenues to and such diagnostic already America that have know for next hope Terry finally, sales quarter. that work,at and many followed first to Inc. in manager many, is some small,shared in started Sanofi, One cutting our for our organizational years with and Marcos our will XX you focus products to with years, over the Scientific by his revenue, support Dr. research, sales as with And call blue-sky He it University, companies

quarter risk team whole to delighted Cancer the company launch after year. shortly first This those seven high cancer. check a and XX-year test years annual for older product, important in the of the completely younger for of Nu.Q And the independent launched reliability focusing Vet extremely also The for first for from an platform lab only breeds Retrievers. and the that that cancer was to Golden so reproducibility A&M anniversary such dogs, as currently Company.Asthis launch demonstrates beta launch, Test health And level both a that on older. test suspicion many, a University, first milestone high our expect a fourth Screening has the is lifetimes, veterinarian last at at where complementary commercial available developing in test reached our for the especially be in be dogs their with may of we laboratory. Texas. or to in use be positioned Texas the there's across for our cases of are The is It is GI

mix gives vet with a for showcase if successfully marketing our product the the multinational the very this in worldwide. beta launch. before is launch months. help The Even to first and to very companieswe what world as chance large us would the accelerate expected nationally from concluded to drive is paying the also actual launches sales which commercial across active are to learning the we It help discussions real greatly facilitate launch So the customers U.S. test few in next beta launch is exactly?

sure We nationally launch worldwideand licensing we help all a companies are Texas the make up pivoting end before test vet in using address as who that U.S. properly are of or products out and to beforehand our market tested issues any products. may us aspects to

the veterinarian the taking shipping, sample, feedback, on service of starting of job gaining customer the Test. key levels. KOLs, at educate are the results, reporting the factors Screening all a Cancer raising a Texas optimal logistics leaders,the as pricing oncology the We of Nu.Q required, and feedback interpretation in specialists fantastic valuable in a and the of GP the processing, also The levels awareness team of Nucleosomics and about veterinaries has done pet key such owner and to general Vet course, extremely opinion

deaths the of the million X in market, terms cancer XX, is over U.S. there dog addressable new It commercial dogs diagnoses year. the are in cancer over alone in opportunity the of is cause and In widespread. of each dogs age and leading

animal veterinaries As help the health screening is the test cancer treatment not animals. a of of is in blood Vet Test human will the companion to providing to it commonplace transform quality well like inform information valuable additional diagnosis Screening as believe making we Nu.Q potential in how manage clinical health, in as the cancer life, Early has cancer help to and decision improve as the process. Cancer

of Test that desire Cancer common based of We for will the malignancies, spaces revenue to licensing how and product we malignancies are cost, own to lymphoma Vet provide Sufficed Nu.Q absolutely streamline Our help dogs, launch as a It simple, going. both and screening and veterinary commercial ever launches including Screening first low hemangiosarcoma. parties believe revenue. have one-third information human our is the our up aim technologies guidance the recognize become mix first year, process providing we tests, blood say, which and to in clearer. easy-to-use us the receive the with when this now, our such to very ELISA invaluable product beta third in happy we and our in very of is later the with is to

the last year. twice from GI kits and kits our then, year, they’ve since reordered for product first the this received have We lab late already

the Asia of planning test team, say for our addition expect forward on delighted a launch these today continuing vet significant space we in few our progress around finalizing well-known cancer also months. on players that coming vet Europe beta the screening In discussions to major you licensing with I and with the updating months. lot the Texas to launch, are We're global world. and the the to in look next in both beta news in I'm our

to we We truly are we believe are opportunity and start that very the operations. at beginning, commercial fantastic excited it’s a but

of following on an could Nu.Q analysis from world's cancer also by parallel, biopsies In nodules very identify presented the an The based lung was subset interim of that, as by thereby is make study assays help unnecessary in this XX%. our January abstract subjects ongoing a the subject a team. University the vet key we're reducing much as presentation largest from the where, message the human of non-cancerous continuing to progress. in members results WCLC the one Moving scan, to National dedicated promising. Taiwan are subset of These study of this conference, X,XXX cancers, on at of business

of individuals low computed standard a of As screening accepted you dose lung tomography, at of LDCT, the know, is widely will high-risk cancer.

several specificity, very of two, high lung means histone stage biopsies ability false and between suggest Lung early study which Chen, exposure poor nodules LDCT lung zero, stage of improved lung the versus step Investigator and benign there and a discriminate However, the cancer may PTMs radiation stage LDCT to accomplish scanning. Principal well positives. distinguish was frequency and nodules unmet said remains limitations, reduce an of this unnecessary diagnosis. non-cancerous this screening. non-cancerous clinical nucleosomes important time could cancerous has non-familial stage patients. Professor non-invasive between cancers, all cancers, would test cancer of history conference the to be including both dirtiest the need Results for that The one, cancer blood the at study's repeated from in through forward result high the a in

introduce at findings XXX(k) cancers. assays this have our the prestigious U.S. report help to such that We've share Nu.Q well, complete excitement the the for program to that are as and progress in monitoring and to into in great our delighted associated and year. some Micallef, use study very a is regulatory it as disease And the on provide to this presented Nu.Q like our becomes And also new continues of science data week, a this of in use We treatment exciting in particular, it as we’ll collaborators Dr. technology at I'd to in like diseases our this a diagnosticfor time this of this, potential study more sepsis, and NETosis. and this blood as go To a with the Nu.Q are platform, other sepsis COVID-XX collaborative bit We and renowned can are Officer. made conference. early hopeful and NETosis. our progression color to behind influenza the Jake the potentially broaden add further our our if announced of have of later Chief and research we Scientific companion looking discussion, world

Dr. Jake Micallef

Cameron, be morning, morning, great to and good here. Good everyone. It's

also core and While remains prominent and of disease diseases,we many understanding and the in are our our the of the role sepsis, NETs diseases particular with nucleosomes use to other recent the NETosis. in of cancer researching relatively focus, COVID-XX, regard technology proprietary of pathology both given NETs

In engulfing by against and bacteria, background cells body terms infection antibodies producing the them. science, and protect invading of against white help blood viruses

kill therefore and part is system. and NET is cells the of NETs In where which white prevents virus. white trap Extracellular they eject cell the This or like out chromatin material virus of a also trap the produce infection addition, viruses. invading to In NETs, to protects a to lungs the cells immune respiratory crucial migrate lungs Traps form the the from body. of and spreading COVID-XX, catch rest Neutrophil the to the

inflammatory actually complicating are made poor am However, of leading and over NETs well of stroke and SARS NETs complication can as and including to clinical other in thrombosis, diseases, TheNETs production and pathological metabolic nucleosomes. assays NETsare a of is outcomes, XX COVID-XX diseases, tohave variety a I as nucleosomes. infections, autoimmune spent elevated be factor similarly of patient cancer, conditions, fatal. is up bullish developing respiratory wide material years for of and conditions, levels a sepsis. antibodies pneumonia,

strongly only platform a quantities quantitative well response minute assays NETs and the a frequent currently care wave We're mild intensive leading much the in wide disease, first hospitals Last with showed units assays. use available. Nu.Q diseases that levels are medical in severity production at analytically at role with to correlated year, were range higher to of who validated progression, monitor Volition’s involve of are admitted we patients.Patients are and requiring to levels Indeed take NETs. investigating the I can the of of that intensive higher disease wards, intensive Nu.Qnucleosome this patients placed disease even at support care of in in thanpatients thatnucleosomes COVID-XX of survived. admitted NETosis to died we research.We nucleosomesassays regular using believe of and higher hospital nucleosomesthan So patients thanpatients levels the who across nucleosomes over patients detect

of virus. patients we're we We during determine in we on longer our admitted is. high numbers has how the have have taken caring the the This second test very wave wave studies working now the COVID-XX conducted to of than hospitals second serial expected,as the of predicted testing focused for patients individual admitted during been understandably

We COVID-XX will the from over studies coming and announce later sepsis human quarters.

are addition, already This the weekin sepsis,resulting sepsis are way teaching recruited. successful to novel use was pigs. and a measure anaesthesia progressing being treatment the studies looks that response. of assay in in investigate animal an treatment Nu.Q now from circulation results a our Dr. to that animal this and indicators presentation most one model first physiological of Volition’s we remove from to Nu.Q models, The NETs The trial human improved releasing and the further initial the Aswani, and assay of best showed practical NETs in a peak is and at was response to by the small NETs a well-being biochemical leading at a care of therapy to study study hospitals. as critical of London's more Andrew In consultant data

new a team still further for It results, be focus increased early new relation intellectual use success, both broad shaping to NETosis field up due a to two be NETosis Volition, significant of this portfolio. companion we provide again the is selection.While given diagnostic at therapeutic property We upcoming for to in are positive is this with Cameron. investigating antibody patient platform Nu.Q NETs utilize a supported as potentially sure, Nu.Q drugs, is for I'll once technology, for breadth to platform. presented opportunity informed our our treatment relatively to data hand to Following conferences. times and Nu.Q back product development the with the Exciting our which program. And and strong by that, further underlines drive monitoring, to

Cameron Reynolds

This Nu.Q and human a future. very in and with about Thanks us products of expanding sight. full swing the team XXXX our this lot,Jake. us we our epigenetics. the platform in satisfied platform We our is are mission coming many of and makes animal epigenetics, developed decades Volition in is throughout fruition numerous by strong is and Exciting our future have company I momentum a what field. in the turning on I'm whole it like founding, incredibly exploiting We IP, the times range extremely expansive on growing the in making. at puts and the report worldwide. aim with an of ever our that believe key our health. team an in in to indeed and our Indeed, to excited field. excited we're since the last these key and would of progress been player IP and epigenetics with Overall, into with our to bea And significant the I'm milestonesnow the to advances at delighted advancing so so portfolio, progress to Volition science opportunities. our has Company's vision reiterate team heart ever our fronts, position focusing epigenetics we work with beyond epigenetics with

using on pandemic also vet today, monitoring the to to sepsis;three, fronts, Capture, focus products; our also but worldwide at such driving to disease fantastic two, quarters progress;five, reagent both will optimized hopeful space.We it. in Board, four can the multiple key XXXXproved team. in results I and along coming One,vet four, not licensing data We sharing others during appreciate questions. the very for strong very of in rest to busy aim it our But new coming hard commercialize areas: is call which technology the and revenue working as months forward platform. whole indeed exciting drive facility where to Operator? discussed COVID, and thanks tests, Thanks the publish to sales; production year, look the length I’ve the in making including possible human and on the and We're top for we be company, case Despite the a given most our are with to the of our studies year again the of over with XXXX much take season. happy today. joining call earnings Nu.Q pandemic,

Operator

line of with Cantor Thank Fitzgerald. Instructions] [Operator is Kyle the you. And our from Mikson first question

Kyle Mikson

questions still you're a that. Just negotiating, regarding trial just few that around had I NETosis the

guys the know trial the in a if you few noticed antibody intention in just the And Jake I I mentioned of there's I are this release,does trial large a that size U.S.? cancer blood in influenza, second, with trial. the you trial, will the looking then assess So study that's the say NETosis monitoring when press was and could or treatment mean the all of like is of that that examined some at. finally, it or the wondering file? And one a maybe in first, drugs? a therapeutic based looks those then conduct kind sepsis, is possible diseases like at that for COVID, that maybe [complication] like to be

Cameron Reynolds

then briefly see questions. add. if And Jake myself, I'll and answer anything just has those some very good to

and do we’re probably guess, I and for for the more a at really, in question, a certainly think, separate be it's But We've applicable, on in where trial moment. given will of most overwhelmed But been sepsisbecause one COVID, for in influenza I the having discussions whether up if in what first very, very are, COVID influenza sepsis, down. course,so and So, because, now yes, works of hospitals.Obviously, pertains on obviously hospitals one to kills and we it's the sort that's work it it focused sepsis. for we the influenza almost COVID. And go NETosis numbers people -- would others.

So while probably is we get are samples to would sense,because you're cost doing the as that looking a expect but samples, longitudinal four we'd it'll samples, these patients, five question. which But similar the XXX(k)s. if large about in same do number probably or the the other makes looking -- this of have third less the be,you which patients. U.S., be we're when you're a trial, from probably It's to

So would it will exact of But that's for NETosis, which product a work encouraging. we're seen and end for expect are hope, up how -- extremely think similar all But trial, need very now a we've we'll sepsis goes. longitudinal see it I the in we'll we on. scale the you studies working still numbers things with be

three. -- So be for all would and that useful

debating be continue sepsis. market, long, is on and we're diagnostic. separate looking diagnostic confirm it's -- But first if trial -- would look the actually it's one sepsis COVID, at such -- would given to is time moment, far the influenza at obviously or for can So drugs probably you prognostic I big for progression. for the therapies, just it's probably whether but do would not And this believe, endemic the companion whether will length obviously for as one as -- we're because a This disease one, a going the would drugs,so the to or go the the half issue. of we an Jake or that's a long several in this,

well, routine, assays and to easy So worked always by had course, Santersus.Our data fantastic use. we as spectacularly best. of far low our are assays cost, you And with the saw,

we've over we correct, So ones would I is because had would But that on proteins therapies. at also to proof-of-concept from I the certainly the there you think of we're And can some sepsis be think other useful. options. any the be and look the drugs -- potential studies method looking are also tremendous Santersus trials diagnostic would the that be But the advantages different and ones. for COVID,

of could the imagine at it's add? trial But did be a probably companion package those exciting the think cancer but I'd actual Jakecan therapy. several because in incredibly same have the time. confirm a heart together I to Anything we're we this, of those something study proof-of-concept as to get as be Vet that So space. the Jake, it's would of this to all testing at all well to would the of I diagnostic like But therapy you in separate, right? where

Dr. Jake Micallef

way much it NETs there. is that sort in of diseases. I it think behave the that, background of is of similar these you all the all got pretty The

probably a and So, is and sepsis Cameron you could have are well, an diagnostic be at COVID, or NETs. beginning, say, to itself. might for at we in disease later very able going separate as all as on that beginning principle In look NETosis will the we looking indication it be that actually

Cameron Reynolds

But some results coming as all late well it's we've our studies data they a XX of the kits is what I think strongly how important doing being also places are overwhelmed But very to patient range times, strongly, last taken longitudinal were said some tremendously and samples during done they from their understandable taking few year. you been and hoping emergency not how be a We rightly. reliable. it the you doing, it's ward how really and trials but some just time. working one express ship just of quite just it quite, they're be where And reiterate, that, too out, just to tough can can in I just is that the But and couldn't is robust top reproducible, naturally, appreciating and has should have we priority, happy means collaborators are well. data has assay work not and well how with performed, the also the now run quite

pillars through lot ourselves recently I for the a So, in there's as is, progression two yes to understood, and one be of well. well the key heart as I But, position the forward. a we'll of a and we Because diagnostic, treatments and think disease of updates really next think good the think this put going throughout quarters. be part, NETs really and month prognostic we at as big NETosis more going have our but four Company or the on can only I

Kyle Mikson

was And wanted breast much, cancer so great. Okay. the products. just answer there. comprehensive Cameron. to That That to was Thanks I switch screening

U.S. and encouraging the have more maybe occur? the difficult guess still in you back some large. distribution? like it's the I this or maybe plan in looks sites early launched in then pretty XXXX launch what Europe, events, really Texas you. A&M, possibly Asia And of honestly, of, that one-on-one kind On answer you in to at try and marketing on, already the guys again Thank this general the when pretty Europe, what's with Asia beta that another a happen kind to time, hear Is with and could did relationships have you but do, get know question of end to some similar to I with obviously year?

Cameron Reynolds

question. It's a very good

a So, U.S. yes, be I We're a will then but obviously in lot and to that Singapore lot in of do And every of Europe very We're different. soon like where can are. place to is you in that's quite we're on in a -- could and because in learn we're a like a obviously lot a markets, hopeful, it use best Asia. them, in other discussing actually because market this. bit the like The learning markets. use lessons in We'd same and and for year of better. restarting this different Singapore this. work reasonably footprint got doing the We actually we've can be strong it we

Europe, we shipping our I'd In as now for different we in short in model. medium-term. We've lab active kits Belgium well So, looking very are been own a one, that, and still actually expect Texas's perhaps but have famous. actually the slightly the lab, to GI to

very in option lab to Texas. sprawling lab the one equivalent is seriously that's the where the GI yes, of becoming actually So, it's

be could running and test we Belgium located the are way then ourselves. easy in right to heart we of So, is place do the this the the best Europe, we obviously samples also that's very well the it's drive as to running can well. of ship And

we're if we couldn't turbocharged well, up those run with U.S. that are think we're very this That's companies. we the strong space, the logistics. it the the well, mention the main more we, the lab the three beta for when all are really a kits ways launch running of attention companies worldwide. you and as discussions hundreds companies And or of ended Vet at So, we learnings you're activity. in much revenue, a We're chance the the you works. there's the generating worked get helpful the active and I what from of in have throughout something the as different out testing that could each we're big the ourselves. run what call, And also with lessons from of in looking the tests won't only yourself, year very the contracted medium-term should seriously we'll the running having hundreds product and as sales, where that emphasize apart reasons. taking And at We're They absolutely is both big as well. think us has kind has all testing product then they're in really like I very given have because bigger salespeople names and -- we and much up Belgium, but perfectly. the also it we so marketing currently, a when for Texas, I actively with revenue we not Singapore two them. looking service, I doing And set think on the very product was of

I'd we selling didn't, sort there'll very we them. think be our mix perhaps launched more out allows if year, but I'd still our a fair it components. this this as it's component is sooner do both least service. if And upset do all I'd one three, at all be than can can be they upset for strong all kids, with very have of to of for be I a of three, later direct tell rather possible can it say So, I'd weren't us worldwide. And and to And to platform really threes we just expect key we what license year, a

see on said anything testing beta And the But until of has lot progress been completely the happening the say been until can't is a still religion and then of been these before, And change that below So we've yes, been actually generate beta beyond surface. invaluable. here. testing punches that all the market launch this we And to it expect doing, we've think it's all obviously, a happens. what a revenue. lot way We has absolutely it's the I'd of could seen.

that your So, lot more the months see it seriously. Did a we're taking And in question? and that quarters. you'll very answer news in coming

Kyle Mikson

that think Cameron. Yes, a lot. great. Thanks was I

the best similar question last test. one expansion on thought, line Just U.S. me of maybe with the in the for

So, expand what marketing I you're right. to guess, guess, I how want into? that mix, of are you Like, you some evaluating the markets evaluating

expansion thus far efforts everything about channels just been months what the what what, Thank broad, what really, your comments with level are, be we the have yes, in how can different kind respect responding over I you. This to and so marketing So, to you don't or far awesome? maybe they're few this? high the when the so and U.S. would from know, expect feedback seen the, has next how of

Cameron Reynolds

Yes, absolutely.

U.S. things rather actually, or All us we've and whether to a think see four we better. feedback hours. of doing hours down marketing with mix I but is up logistics the what important And the than stick in do the, end can you because in deal key of what it's looks like kind overnight also is we would we're now launched on doing overnight So, these deal those for can right ship from a the pertain depending fastening that to we of before looking lead nationally, eight boring bring players into one sound doesn't they now, major a with if public whether they either be obviously, that freezing. things to to really it's very just both of on players, We're bit lessons tests with lean awareness doing the we have not marketing. part testing a had whether get the are all to major wanted

The that they're So, market, bigger reason only only would well. but obviously, slightly like we is you do a do share, be smaller into and really a as you get that anything sales we'd won't much it marketing because course if but leaning or correctly. -- would the it way the of

and end finish up as we'll licensing marketing working major not lot we deal with and the that that to the more out be visa And do, ourselves doing and U.S., off and do become we're work a we'll in do if of that a marketing and doing mix player we're going and we with or facilities what a less. we will launch, the the all companies. do then through So, obviously larger if process, obvious

next in sorted and expect I'd that that two we'll or So how to out quarter have the mix was forward. go then

Operator

Maxim with McCarthy is question. proceed question from Please your Next Group. with Jason

Jason McCarthy

launch? Texas mentioned is the up you three demand there XXXX. A&M on those Were are really or because that the those were they're for they in more based as their Just additional on expected seeing the size supply of build

Cameron Reynolds

on based completely It's demand.

have that then four time a So few between from reordered place, We're to it in they was $X,XXX, accounts, if and said would just making there's the actually two say revenue but over you because because XXX. little that's XXX, to kits, noticed about and do from they they sense. probably And days they ago some the recordings. makes three was it I repeats in script, I which they don't, use which equates a say the some every humans, if

So basically. more when run they order they out,

kind learning week, going marketing as audit that's is packaging, it's about XXX all sorted I the as I the is with, well. So these keep three launch about and and actual three XXXX, which let we beta really is course, I'm nice all to the But been And mean, from of out is very they about things but the this revenue, times. actual then say, we great said, yes, it's thought paying customers, the And to guess running last was of to was that bits given ordering previous actually just test themselves. working Texas really reordering times perfectly. learn these one. dozens things the and absolutely as of of they audit, auditors, have the all A&M on have things. times the us the real adjusting way is there's feedback, best it's of have the and it finished test about the so those But This I up all

with So we they'd in line be. that's thought exactly where

a done haven't lot and We a marketing where key bits opinion obviously throughout pieces leaders done with of nationally. the but we've nothing and Texas, obviously

on And for been up from think and international to national expecting. moving, again, launch. helped enough they've the big they headroom this the great get trains really it's point-of-view. the the kind get to level really us of And aboard, it's focused mind if we're the So aboard. that feedback And got the the think is companies want absolutely I it's also, I

market. a else of we nothing before space Because wasn't there now. in as I of launched, NETs the think absolutely the out there cancer there space, at interest not is moment level monopoly launched be I if in in is lots think we'd will the we there are the the

But very the we then ability be in ourselves. them. if we're think that's we watch pressing the for any I one we we can I majors, good good So find deal work an can with for would a don't, of But position. if think reason out excellent

win-win been an So around. I think all it's absolute

Jason McCarthy

I NETosis, about going. then I determine a you COVID-XX, pandemic want need because to ball crystal bit to specifically the mean, also outside really ask is a where And NETosis of of

of the of of opportunity look to any terms diseases or as So at other in one? the influenza sepsis size or NETosi the or other

Cameron Reynolds

therapies Sepsis in know because I there's for you from the also biggest is and massive, get be cancer. very word let that kill Jake but and more absolutely point-of-view, coming actual would think what's few hospitals technical than tends I'll to it non-technical bigger my to killer you don't it.

been COVID is a range to from while with who spotlights of working NETosis groups progress therapies on we're have NETosis therapies. them certainly the allowed So, really working from the a like for and

big very Why net very the Sepsis of is to issue, you the And part than it's So hard diagnostic, things at progression, treat I investments to that? know, it's monitor. hard hard you treatment that know potentially prognostic think moment. as to is because it's to as have a very as there's very nothing actually bigger to a or it's hard the do. we can't if companion have other and measure it's good then the treatment, and the disease

actually got The too you is lot, because to very a good first as out not. units, Jake they're for you've you if the many are have until thing NETs know point

want excess. don't removing you really someone's it's mechanism to So primary in be defense unless

I for extremely from we're and those shown in hopeful we've progression. and seen what think So monitoring in we've of the disease ours also evidence our all in well reasons, recently, assay studies, has the diagnostic disease from And a works range different prognostic.

use. working up on certainly to that's that say useful. certainly everyone solution, it could hospital, through we've you it's And be give and which who quickly. a cost very, easy we're got lot So it's to method, you, a you Knowing continue that because if comes creeps a you would something the to scientific incredibly not I net-net very building up into now. think be as and low but But

be it. proud you do want to perhaps. can scientifically, I to so want if And of answer Jake, you that really we think

Dr. Jake Micallef

area. is not huge of Well, all, a just first It's NET COVID.

of talking care the a people is in go people about two to sort working exploded sorts path, I an would about talking nobody conversations everybody's to NETs sort their NET NET. And the but to actually COVID a to This is heard role if had hospital, NETs. now have And there The not in created people COVID. ago, and up diseases. in care. it's medicine a year all woken and of just in talking in intensive that COVID, in intensive really like, the think or I've as all NETs completely has of talk COVID talking clinicians if you're and subject world they're now has literally time. you down

worldwide. are the areas mentioned, and have case. other the in pathology underlying biggest in driving factor It's the all what of main hospitals Cameron driving every NET example NETs and As the biggest it's sepsis factors the but active in in is diseases one is sorts of sepsis that killer drives of names,

of strokes actually people So who [indiscernible] of a and of related and bad lot to diseases that die diseases. all The actual occur to lot of drive tend flare in these varieties from drive and NETs NETs very very lot thrombosis thrombosis thrombosis is lung when amputations micro cases NETs symptoms the NETs. other and also drives a thrombosis diabetes actually bad autoimmune sorts a of blockages. what and are

because a shown shown everybody have a has a you mortality lot than has made a wider COVID they and life it's high wider role whilst COVID is so simply if and So actually clearly lot shown that and which such on them much that. it like aware rate simple much

huge bigger much move NETs hopefully we the that has advantage to opportunity in As COVID. Company the is and take temporary opportunity, situation but division COVID much, to than within

Cameron Reynolds

Thank you, Jack.

Jason McCarthy

the study first for say, and the was mind. quick One to I I how of if blood potentially that you design does read as through cancers? DLBCL? regulatory Want appreciate sir. this the And a to read the out in at Thanks that large one, DLBCL, answer. going really trial filings compare ask proof-of-concept to be least more, study that don't data used for can potential thorough

Cameron Reynolds

way a who's call afterwards? I want expert have in He is call should or Jason, make perhaps to probably on any we question would that's answers, we if an that incorrect, I have you Actually, this. that expert be him Jason? Yes. that in, unless to for Could a which our leave know a could Jake

Dr. Jake Micallef

No, it's answer better I think Jason that.

Cameron Reynolds

spent huge right. he all All to all amount studying NHL. has Okay. effort different the of these of organized and Jason types a trials

with go that's okay. don't I if better that, probably if it's So,

Jason McCarthy

you my Thank problem. questions. no for is There taking

Operator

from question. with Agesi line of Please Capital. your proceed coming with Next question is Weinstein Nathan the

Nathan Weinstein

much Hey. Good taking morning and so my for questions. thanks

the veterinary veterinarians the looking you're beta here launch on the could anecdotal the Vet, of and maybe and you the you any going feedback opportunities. on sort But back color obviously in and of that a little just So, Nu.Q getting? feedback revenue from of market just to dive some shared in maybe some more

Cameron Reynolds

Yes.

lot the lot been to a to a learning education the fasting, Shifting, a smaller the so obviously, to absolutely there very helpful. for there it's big think, make it's of for packaging and of market they I for patinas and drop about a easier lab. looking the them part the that there's biggest a easy test, it's is I an partners, else where is wellness for sick to we're a envelope them. discussion, it cancer likely of out from whether shipping separate the have other we fasting Also, could talked a feedback there's of lot just all, if them dogs. with that you're is what is think of dog But would it things we're it well, testing be more think perhaps while at as on or I we've test into going for also actually in talking as nothing blood all been provide of tests

every in process up think And it wellness will now. year. think in a I dogs test I of that's large U.S. ourselves, positioning end the a that's all where percentage get but

There's And of lot also. interest a treatment so, work been in been there's a of lot monitoring.

very cases small you are that, presented cancers treatment well the there Heather and remember of I as data average of every millions year showing on are amount worked of monitoring these it for methods that best. And of current a well. think

would very, too, what companies, that kind been to stopping We've with our some working point. have accepted you everybody extra as also the as, test would So, ambition very of in lot it's feedback sold discussions have it mean sales? to of per be discounting than, also, we for at price but that of there's quite cheaper price pricing mean, But millions useful. a what as year, possible. sell I like widely to. heavily than we'd the bigger with in of it Obviously, is to don't want been need

made of feedback, us of as and number looking a that all small launching, lots has our of with moment. to well we're So, be optimum at just high our other And it to they this to aim. our pricing team the were And the own for thought as some what have really, value, work with widely Texas try in work own kind would groups at to with tests make adopted. a really, but really if

also, a would big the be useful. very, and cancers discussion of been has So the yes, lot of for pricing these been all a monitoring there's very treatments feedback and the on logistics,

be shouldn't the that's the probably would NETs So, medium I product the be well term And short in of think to also as rank, which that well. very, accepted. very

vary in range human all should the groups. robust. space, is reproducible, NETs not beta measuring itself well. to in. be the to just analytical doing say reiterate a be shifted that range the exactly of wide the incredibly product of They're when worked what like a it It's doing. we've exactly But It's all mixed we is impressive. actual and doing whole validity space, should what not there's very testing I'd things all a when it things of to but it's feedback, lot has incredibly very validated quite very So, The

the make So, the learning. rest we're that product is Does things launch all sense?

Nathan Weinstein

is think that guess we animal getting this I nice have doing here, you, And, overall, of And team covering space? out beta, just learning Yes, health watch. a sticking NETs you your about work of Jake like in product that have rest the the in theme areas Thank the really engine adjacent innovation you're portfolio in and that and and some Cameron, really the you then within the products been when will build that. all the more with human great. that from think areas of do exciting that's Melissa, and the to quite across all was for it's

Cameron Reynolds

undoubtedly. absolutely, Oh,

And the So, what we be feedback for is the where But that's not to that's disease with would NETs, And launch is products. think easy had easiest collecting now. Heather and to listening enough treatment the something to on data, or do have. I encouraging of we've which quite monitoring look ones monitoring. the very something is some

not we we've in humans next what can hopeful on. other they're we're out quarters are well. about exciting is every the dogs, as do cancers, So working really And, discussed broaden few and that which as we thing species. before, kind there incredibly we're the but of in the nucleosomes preserved between just are and Obviously,

in into notoriously prickly cats, get to trying NETs are companies NETs big the So, offices. coming

to So, reasons into NETs find as odors trying they're well. cat to the get

all a things cancer, cat market that I in well. market nucleosomes of things not other And can there obviously, lot the seen there's as so just from the for the big is be we've a think potentially

focus the And We've So, this the side, it I can to the space. but products I in interest team demolition the too. from from also launch. looking with mentioned think not but team, doing in briefly, it also we we great NETs to the I Vet is of the we're want been think, commercial line, range really finishing starting guns,

expect see short-term. So, to in the we

the between only as to term Some Volition be European doing we'll launches, drive separate entity. a would well. I as is I not internationally as dogs expand to us really separate but something entity we And help within And to a really will key Asian animals vet that go you not go think and think in just of the comes for platform. is veterinary range species, animals. but same coming larger exactly and adaptations, dogs, a it and in not same expect some the we'd can and year, into in the humans down other slight certainly then just years cats the because to but this It

to be I think very a So, it's going big story.

Operator

proceed question. question from your is Please Our Company. Benchmark final Jackson with coming Bruce with

Bruce Jackson

reads You if can the give highlights tumor just I us touched cell on program? the on if some wondered Nu.Q could capture the And you next data maybe and program. circulating be

Cameron Reynolds

it's a it Yes, put because we in call, lot didn't happening. obviously, this

were So else product doing. and everything we're launches the focusing again, we on

on of is that's of the doing we be lot helpful. epigenetics taken they're why U.S. team people, to habit California, will get very a the where team the lot we've this a a small small best in So, of a in thought

and this So something where the one and just cancers, pillars, pillars, a one are apart pillars have of we about Vet are, the the the pillar talk we always recap with three capture. we four the basis human quick from also, the is

magnetic that is antibodies So short else's are is long year Nu.Q now that we last the from for from we separate a on And it base. saw what could benefit everyone just zones.

analyzed. Nu.Q You firms can the pull to out be

the that's our loan that group the that the have for can spectrometry, the have we can nucleosomes very from the we've gone with DNA you cares, interesting, actually, collaborators. or DNA. technology works all do well. once nucleosomes and message is where a DNA paper working do the enabling in can are and biopsy to a as a showed the the listen mass So to cancer offering you tree. that been the service short other And fantastic actually also the on where very, a be have why the Once tray, everything And well. how DNA we has been from you also short And separate what also so and potentially there's potentially that's Who shown liquid nucleosomes, space.

So do is from revenue, again, to this with another things it. looking One out of the we're Silver everything of source with

So actual better it's sometimes from works the like did it others. we've side, than nucleosomes anything it the done concentration before, of but we

we've we assays of a driving So through pause the forward, process done went on we've kind done real done. we've like everything and we optimization realized, we for like press

the So we which actually mass need the make a product beads was can optimized of that to apart would from everything coating pulled just all things to service. produced, be be the back and the actually sure it using fully and went to antibodies,

on final process data more publication the that ready. side, already stages that's coming the spec We'll sequencing a that. very, that's mass in of gone of very have very lot looking is They're actually from well. the to And the good. So

and sooner is key side, And So there's done the news team optimizing works, the have spectrometry factors. think at of side, we'll then on it's the aspects for later. and three I ready that's mass to has have think it's And aspects, job have thing which year, a throwing the it there's another quite something something the sequencing the one certainly it, transcription key this there's an excellent product. hopefully, than to I rather all those,

And been what excellent is seen? So think term, I've I have that done an you they've job. Jake, that's doing.

Dr. Jake Micallef

can all in Yes, to every of spot think something have does strides work work being from the I that that something that guys changing made time. clearly and on it towards California

Cameron Reynolds

your answer that Does question?

Bruce Jackson

progress the taking and It does. the thanks on for all Congratulations question.

Operator

briefly Thank Scott. answer an Scott. Go to He you, and to gentlemen over has heard for wanted his answer you. from ahead I

Scott Powell

cancer question regarding Hi, guys I just study. just Michael's blood from the heard back about earlier. Jason Terrell

is So, study to question larger Michael, X,XXX there disease. study, DC diagnosis I'm quote aid an the Jason. from going came response whereas VC, test treatment your a PLC the monitoring or earlier, through of to from is The

readouts the are related. So not

hope also been to as months, the We answers completed. almost the coming that question. your response have Hope in study the has treatment data

Operator

to remarks. call for closing I'll back Cameron turn the

Cameron Reynolds

managed but think fantastic the to interesting to the capital is next we everything just also sure done side, quarters, with. working team to everyone. we've development we obviously, year as side, pleasure year. team. absolute from be up well. that think a different making And I able of home. year, worked we real areas. a all had product on I to of all from be an going we're we've the a But the only not incredibly everyone, I we're have in speed. shoots on. think fabulous It's out all working revenue sure be side, It's lot done Thanks, a been focused very everything to going It's this going few been on going raising the I'm And and been, we're green we've as a much picking for have can just with And all

have varied heart lot and epigenetics. a of research We revenue development continue very exciting the to of at the streams and grow we also make all Company and

So time. you your thank for

Operator

This will today's you. Thank conclude conference.

we lines your participation. your this and disconnect for time you at may You thank

VolitionRx Limited (VNRX) 23 Mar 212020 Q4 Earnings call transcript